医学
恶化
内科学
气胸
慢性阻塞性肺病
人口
随机对照试验
临床终点
肺功能测试
外科
环境卫生
作者
Ralf Eberhardt,Dirk‐Jan Slebos,Felix J.F. Herth,Kaid Darwiche,Manfred Wagner,Christoph Petermann,R Hübner,Franz Stanzel,Arschang Valipour
标识
DOI:10.1183/13993003.congress-2016.oa470
摘要
Background: Endobronchial valve (EBV) therapy improves lung function, exercise capacity and quality of life in patients with advanced heterogeneous emphysema. Limited data exist on the use of EBV in patients with homogeneous emphysema. Aims and Objectives: Evaluate effectiveness of EBV placement in patients with severe homogeneous emphysema. Methods: Prospective multicenter RCT enrolled 183 patients with hyperinflation (FEV1 ≤45% pred., RV ≥200% pred.), and severe homogeneous emphysema, confirmed by quantitative HRCT and perfusion scan. 93 patients ([male]/[female]:36/57; mean age: 63.8y) with negative collateral ventilation (assessed by Chartis System) were randomized to either unilateral complete EBV treatment (Zephyr valves; n=43) or standard medical care (SoC; n=50) at 8 centres. The primary end point was ΔFEV1% at 90 days. Secondary endpoints were pulmonary function tests (PFT), 6-Minute-Walk-Distance (6MWD), SGRQ (St. Georges Respiratory Questionnaire), and safety. Results:Outcome measures for ITT population at 90 days were: Serious adverse events (EBV vs SoC patients) included: pneumothorax 25.6% vs 0% and COPD exacerbation 18.6% vs 12.0%. There were no deaths in the EBV group and 2 deaths in the SoC group. Conclusion: EBV treatment resulted in clinically and statistically significant improvements in pulmonary function, exercise capacity and quality of life in patients with severe homogenous emphysema and negative collateral ventilation.
科研通智能强力驱动
Strongly Powered by AbleSci AI